Makana Therapeutics
Developer of gene-edited swine and associated assays intended to enable pig-to-human transplantation. The organization focuses on removal of pig xenoantigen genes, optimized cloning and reproduction methods to produce clinical-grade animals, development and validation of histocompatibility and pathogen-screening assays, and IND-enabling preclinical xenotransplantation studies in preparation for human trials.
Industries
Nr. of Employees
small (1-50)
Makana Therapeutics
Miami, Florida, United States, North America
Products
Gene-edited pigs with reduced xenoantigen expression
Swine genetically modified to eliminate key xenoantigen genes (triple-gene knockout and additional SLA DR knockout) intended to reduce human antibody binding and organ rejection risk.
Gene-edited pigs with reduced xenoantigen expression
Swine genetically modified to eliminate key xenoantigen genes (triple-gene knockout and additional SLA DR knockout) intended to reduce human antibody binding and organ rejection risk.
Services
Preclinical xenotransplantation studies
Design and execution of translational large-animal xenotransplantation experiments to evaluate graft survival, immunosuppression regimens, and candidate organ genetics.
Patient selection and crossmatch testing
Histocompatibility and crossmatch assays to identify human patients with low or no pre-existing anti-pig antibodies for potential xenotransplant eligibility.
Pathogen screening laboratory services
Molecular diagnostic screening and assay development for a panel of pathogens relevant to animal donors and human recipients.
Breeding and supply of clinical-grade gene-edited pigs
Production and scaled breeding of gene-edited pigs engineered to reduce xenoantigen expression for use in preclinical research and planned clinical programs.
Preclinical xenotransplantation studies
Design and execution of translational large-animal xenotransplantation experiments to evaluate graft survival, immunosuppression regimens, and candidate organ genetics.
Patient selection and crossmatch testing
Histocompatibility and crossmatch assays to identify human patients with low or no pre-existing anti-pig antibodies for potential xenotransplant eligibility.
Pathogen screening laboratory services
Molecular diagnostic screening and assay development for a panel of pathogens relevant to animal donors and human recipients.
Breeding and supply of clinical-grade gene-edited pigs
Production and scaled breeding of gene-edited pigs engineered to reduce xenoantigen expression for use in preclinical research and planned clinical programs.
Expertise Areas
- Xenotransplantation
- Genetic engineering of donor animals
- Large-animal preclinical transplant models
- Histocompatibility and crossmatch testing
Key Technologies
- CRISPR/Cas9 gene editing
- Gene knockout strategies
- Somatic cell nuclear transfer (SCNT) / cloning
- Flow cytometry